Skip to Main Content
Phase IIA

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

  • Study HIC#:2000030395
  • Last Updated:04/21/2023

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.

  • Age50 years - 85 years
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Jeanine L. May

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Trial Purpose and Description

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.

Eligibility Criteria

Inclusion Criteria:

  • Meets diagnostic criteria for apathy in neurocognitive disorders clinically significant apathy
  • Mild to Moderate Dementia (AD, FTD, VAD, or DLB)

Exclusion Criteria:

  • Other significant psychiatric disorder(s)
  • Other neurological disorders (other than AD, FTD, VAD, or DLB)

Principal Investigator

Sub-Investigator

For more information about this study, including how to volunteer, contact: